Morgan Stanley has increased its price target for Cardinal Health (CAH) to $286 from $265, while maintaining an 'Overweight' rating. This adjustment suggests a potential upside of 13.9% from the stock's closing price on October 29, 2026, indicating a positive outlook from the analyst firm.
Morgan Stanley, a prominent investment bank, has raised its price target for Cardinal Health (CAH) from $265 to $286. This action, coupled with the reaffirmation of an 'Overweight' rating, signals increased confidence in CAH's future performance. This is significant for investors as it provides an updated valuation and a positive endorsement from a major financial institution. The short-term implication is a potential boost in investor sentiment and possibly the stock price, while the long-term implication reinforces a positive outlook for the company. A key opportunity for traders is to consider the implied 13.9% upside as a potential entry point or confirmation of existing positions.